Heparin market growth is expected to be progressive over 2022-2028 on grounds of the growing geriatric population worldwide and rising prevalence of cardiovascular diseases. As per CDC statistics, 14.2% of people aged 45 years and above in the U.S. are reported to be suffering from coronary heart disease.

Heparin is a blood thinning drug that prevents the formation of blood clots caused by certain medical conditions or procedures. It is also used before a surgery to reduce the risk of blood clots. Overall, the heparin industry is classified into different segments including product, source, applications, distribution channel, and the regional landscape.

In terms of the product segment, the market is bifurcated in low molecular weight heparin and unfractionated heparin. Of these two, the unfractionated heparin market segment is projected to foresee a valuation of $663.5 million by 2028 globally, backed by the drug’s increasing use against venous thromboembolism, a condition where blood clots develop in veins.

Based on the source, heparin industry is divided into porcine and bovine segments. The market share from bovine sector, amongst these, would be worth $56.9 million over the foreseeable timeline. Bovine-based heparin products are extensively used in cardiovascular surgery to alleviate the risks of blood clot during the procedure.

Speaking of applications, the heparin therapy is utilized in coronary artery disease, venous thromboembolism, atrial fibrillation, and others. The coronary artery disease segment was worth $1,117.9 million in 2021 subject to the mounting prevalence of CAD worldwide. CDC statistics suggest that approximately 18.2 million adults aged 20 and older suffer from the disease in the U.S. alone. The use of heparin in acute coronary syndrome is to reduce the progression of intracoronary thrombus and prevent myocardial infarction and fatality.

Considering the distribution channel, the market is fragmented into hospital pharmacy, online pharmacy, and retail pharmacy. Amidst these segments, heparin industry share from hospital pharmacies is slated to record $2,918.6 million, in terms of revenue, by 2028 end. Surging patient inclination towards hospitals owing to impeccable benefits like high quality of care and ease of availability of medicines would complement the market growth.

Regionally, the industry is diversified into North America, Asia Pacific, Europe, Latin America, and Middle East and Africa. Of these regions, the Middle East and Africa heparin market is predicted to depict a CAGR of 1.6% through 2028 attributed to the growing cases of chronic disorders like coronary heart diseases, atrial fibrillation, and others.

On the other hand, Latin America heparin, in 2021, took over a 4.3% business share of the overall market and is poised to expand considerably over the coming years. The increasing risk of thrombosis in the region is producing an impeccable demand for heparin, thus propelling the regional industry trends.